European Commission approves ACAD's DAYBU for Rett syndrome
ACAD says the European Commission approves DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome in the European Union.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.